Navigation Links
Cempra Pharmaceuticals Names Carl Foster Executive Vice President of Business Development
Date:1/5/2011

CHAPEL HILL, N.C., Jan. 5, 2011 /PRNewswire/ -- Cempra Pharmaceuticals announced that Carl Foster has been named Executive Vice President of Business Development.  Mr. Foster will be focusing on business development activities related to the company's two lead antibiotic programs, the next-generation fluoroketolide solithromycin (CEM-101), that is in Phase 2 clinical development for community-acquired bacterial pneumonia (CABP), and TAKSTATM (CEM-102 or fusidic acid), that has completed Phase 2 clinical trials for acute bacterial skin and skin structure infections (aBSSSI) including those caused by methicillin-resistant Staphylococcus aureus (MRSA).

Mr. Foster brings with him over 20 years of industry experience in business development and leadership in the biotechnology, pharmaceutical and diagnostic industries. Most recently, Mr. Foster was the Chief Executive Officer of Juilab, a European-based genomics company. Additionally, he held business development positions at several other development-stage biopharmaceutical companies including King Pharmaceuticals, Praecis Pharmaceuticals, Oxford GlycoSciences and Astra Merck.  Mr. Foster has also served as an advisor to pharmaceutical and biotechnology companies as a consultant and as a Managing Director with Ferghana Partners, Inc., an international investment banking group in New York City.

"Mr. Foster has a proven track record of success in business development," said Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra Pharmaceuticals. "He has extensive experience leading successful pharmaceutical development efforts to help companies maximize their portfolio's potential and capitalize on growth opportunities. His contribution will be vital because of the mid-clinical-stage status of our programs for solithromycin and TAKSTA."

Mr. Foster added, "Cempra's two lead antibiotic candidates not only have a significant commercial potential but also may help
'/>"/>

SOURCE Cempra Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cempra Pharmaceuticals Names Richard Kent, M.D., to Its Board of Directors
2. Cempra Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. Cempra Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
4. Cempra Pharmaceuticals To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17th
5. Presentations of Cempra Pharmaceuticals CEM-102 (fusidic acid) at the Infectious Diseases Society of America Annual Meeting Highlight Properties That Make It an Excellent Anti-MRSA Candidate
6. Data Presented on Cempra Pharmaceuticals CEM-101 at the Infectious Diseases Society of America Annual Meeting Reinforces Potency and Coverage Against Multidrug-Resistant S. Pneumoniae Isolates
7. Jazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference in San Francisco on January 12
8. MAP Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
9. Lexicon Pharmaceuticals to Present at the 29th Annual JPMorgan Healthcare Conference
10. Anadys Pharmaceuticals Initiates Phase IIb Study of ANA598 in HCV Patients
11. Optimer Pharmaceuticals Receives Orphan Drug Designation for Fidaxomicin for the Treatment of Pediatric Clostridium difficile Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... 03, 2015 Research ... of the "Investigation Report on China Phosphocreatine ... The global epidemic trend shows that cardiovascular ... to human health whose incidence and death rate ... to the first. According to the World Health ...
(Date:9/3/2015)... Research and Markets ( ... "Investigation Report on China Tropisetron Market, 2010-2019" report ... entered the market in the Netherlands ... the late 1990s. Tropisetron got administrative protection authorized by ... developer Sandoz submitted application. But it is now a ...
(Date:9/3/2015)... , Sep. 03, 2015 ... the addition of the "Investigation Report on China ... Oxiracetam, a derivative of pyrrolidone, was first synthesized ... whose oral preparation and injection entered the Italian market ... fast after entering China , annual ...
Breaking Medicine Technology:China Phosphocreatine Market Report 2015-2019 2China Tropisetron (Novartis) Market Report 2015-2019 2Investigation Report on China's Oxiracetam Market, 2010-2019 2
... (Nasdaq:,CRYO), a medical device company focused on the treatment ... its pivotal,clinical study for the treatment of atrial fibrillation. ... said, "This is a,major milestone for CryoCor, being the ... for the use of ablation for the treatment of,atrial ...
... Novogen Limited,s subsidiary, Marshall Edwards Inc. (Nasdaq: MSHL ), has ... made the following ... Marshall Edwards, Inc. (Nasdaq: MSHL ) today announced enrolment of ... of,phenoxodiol in women with advanced ovarian cancer resistant or refractory,to platinum-based ...
Cached Medicine Technology:CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation 2CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation 3First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial 2First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial 3First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial 4First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial 5First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial 6
(Date:9/3/2015)... ... 03, 2015 , ... B. E. Smith, the only full-service ... a national chief executive officer recruitment for Melissa Memorial Hospital in ... B. E. Smith has recently placed more than 1,000 healthcare executives into organizations. ...
(Date:9/3/2015)... ... , ... Dr. Robert Winchell has been appointed director of the Trauma Center ... Cornell Medical Center, effective July 27. He will serve on the faculty of Weill ... the critically injured and the development, design and operations of trauma systems. As chief, ...
(Date:9/3/2015)... Angeles, Ca (PRWEB) , ... September 03, 2015 , ... ... is a promising and convenient test that may help patients with oropharyngeal cancer (oral ... cases in the United States are often caused by HPV infections, which have a ...
(Date:9/3/2015)... ... ... Global Vision , the world leader in the development of innovative ... artwork inspection solutions, ScanProof and ArtProof at Packaging Innovations 2015. , ... #F33 , Be the first to get a sneak peek of Intelligent Proofreading. Global ...
(Date:9/3/2015)... , ... September 03, 2015 , ... ... (ACA) triggering cost increases for fully insured employer-sponsored health insurance plans, more employers ... (1,000+ employees), according to data released from the 2014 United Benefit Advisors (UBA) ...
Breaking Medicine News(10 mins):Health News:Melissa Memorial Hospital Retains B. E. Smith to Recruit New CEO 2Health News:Melissa Memorial Hospital Retains B. E. Smith to Recruit New CEO 3Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 2Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 3Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 4Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 5Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 2Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 3Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 2Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 2Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 4
... Ben-Gurion University of the Negev researcher has achieved a ... mouse cells. "This study may open new therapeutic ... pre-pubertal cancer patients at risk of infertility due to ... in adult patients," explains Prof. Mahmoud Huleihel, of BGU,s ...
... Training basic surgical techniques on toy animals before having to ... anxious. At the same time, the use of laboratory animals ... from LIFE - the Faculty of Life Sciences at the ... known as the ,teddy laboratory, strengthens learning and the teaching ...
... Amanda Gardner HealthDay Reporter , MONDAY, Nov. 14 ... of the brain seem to be involved in "chemo brain," ... treatments for breast cancer. According to research in the ... areas of the brain that are involved in planning, attention ...
... 15 (HealthDay News) -- Brainy children are at increased risk ... study says. Researchers analyzed data from nearly 8,000 people ... education and socioeconomic status. The participants, IQ scores were checked ... illegal drugs (marijuana, cocaine, uppers, downers, LSD and heroin) was ...
... Steven Reinberg HealthDay Reporter , TUESDAY, Nov. 15 ... to the statin drug Zocor (simvastatin) to help lower their ... Even though niacin appeared to increase HDL cholesterol -- ... fat in the blood, it did not reduce the risk ...
... breakthrough in understanding what stops a common form of skin ... available to the public in five years. ... Cancer Cell , an international team of scientists led ... University,s Department of Medicine at the Alfred Hospital, has discovered ...
Cached Medicine News:Health News:Surgery on toy animals lessens anxiety of veterinary students 2Health News:Breast Cancer Chemo Tied to Memory Troubles 2Health News:Breast Cancer Chemo Tied to Memory Troubles 3Health News:Smart Kids More Likely to Try Illicit Drugs as Young Adults 2Health News:No Benefit From Niacin for Heart Patients in Study 2Health News:No Benefit From Niacin for Heart Patients in Study 3Health News:Stop signal discovered for skin cancer 2
The Stat-Let lines of disposable lancets are all designed with the goals of providing a safe and easy to achieve capillary blood sampling. All of our lancets can be used by most current models of lan...
... flow while minimizing the pain ... the safety-engineered BD Microtainer Genie ... Lancet offers a full range ... capillary blood collection and protects ...
For patient-friendly and safe capillary blood collection...
... a widely used screening test for determining ... oriented Dispette branded system is considered the ... stamp. No other system meets defined NCCLS/ICSH ... care. Specialized systems are also available for ...
Medicine Products: